Spyre Therapeutics Inc (SYRE)

EBITDA Margin

-205.05%

TTM · Period ending:

SYRE logo

SYRE EBITDA Margin

Latest reported-205.05%
SYRE TTM EBITDA Margin (-296.76% → -205.05%)
High-resolution chart · PNG

SYRE ebitda margin history

Trailing twelve months (TTM). Each value covers four complete reported quarters.

Spyre Therapeutics Inc EBITDA Margin — Trailing twelve months (TTM)
Period endingEBITDA Margin
-205.0456%
-222.4335%
-188.3396%
-22,262.6453%
-14,362.5282%
-9,288.1404%
-6,725.8958%
-6,531.2446%
-3,529.927%
-1,444.0138%
-1,219.8151%
-349.505%
-341.9339%
-440.3445%
-470.7433%
-2,294.0286%
-1,161.7798%
-679.6462%
-486.4877%
-511.5492%
-527.0177%
-530.7507%
-508.7708%
-494.9484%
-470.484%
-407.4708%
-355.0102%
-191.7051%
-184.4864%
-231.7111%
-296.761%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.